What We're Reading: Page 2
Industry reads hand-picked by our editors
Nov 17, 2021
-
The New York Times
F.D.A. Plans to Authorize Pfizer Boosters for All Adults This Week
-
Reuters
Pfizer CFO D'Amelio to retire after 15 years at company
-
Endpoints News
First interchangeable biosimilar launches in the US with a tiny discount on list price
-
The Wall Street Journal
SEC Investigating Cassava Sciences, Developer of Experimental Alzheimer’s Drug
Nov 16, 2021
Nov 15, 2021
-
Bloomberg
What Is in the Covid Vaccine? Why Pfizer Won’t Share Its Formula
-
The Wall Street Journal
In Elizabeth Holmes Trial, Ex-Theranos Employees Cite Culture of Fear and Isolation
-
MIT Technology Review
An E. coli biocomputer solves a maze by sharing the work
-
FiercePharma
2021's Fiercest Women in Life Sciences
Nov 12, 2021
-
Financial Times
AstraZeneca to take profits from Covid vaccine sales
-
FiercePharma
Lundbeck to cut 300 jobs to fuel CGRP migraine drug growth
-
The Washington Post
Top Biden health officials push to make coronavirus booster shots available to all adults
-
Nature
COVID antiviral pills: what scientists still want to know
Nov 11, 2021
Nov 10, 2021
-
The New York Times
Moderna and U.S. at Odds Over Vaccine Patent Rights
-
Reuters
Roche executive says Alzheimer's drug price will be competitive
-
Bloomberg
Canadian Drugmaker Apotex Is Said to Revive Sale Talks
-
The Wall Street Journal
Departing J&J Chief Alex Gorsky Joins Apple’s Board
Nov 09, 2021
-
Science
A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.
-
Bloomberg
Swiss Socialists Want Government to Buy Novartis's Sandoz Unit
-
C&EN
Giving drug researchers control of their data
-
MedPage Today
One Aducanumab Patient, Six Brain Edema Episodes
Previous
